RxDoctor Payments Data

Steve Kang, MD

Foot and Ankle Surgery · Orange, CANPI 1538393889

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Stryker at 54.9% of the total.

$2,727in general payments, 2019–2025

Across 57 payments — averaging $47.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1K
  • Medtronic$696
  • Boston Scientific$115
  • AbbVie$109
  • Biotissue Holdings Inc.$109
  • Johnson & Johnson$61
  • plus $141 from 6 others
$361in research payments, 2019–2025

Across 5 payments — averaging $72.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Masimo Corporation$361

What the payments were for

  • Food & beverage$2,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,727 in reported general payments places this provider in the 55th percentile of 1,126 foot and ankle surgery providers in California.

See all foot and ankle surgery providers in California →

Medicare billing

Part B allowed, 2024
$344,545
Medicare patients
679
Services billed
4,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen87$912
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$812
Gabapentin38$298
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim35$197
Tramadol Hcl35$189
Meloxicam32$122
Cephalexin15$102

Paid to pharmacies, not to this prescriber.

Other foot and ankle surgery in Orange

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →